Navigation Links
Johnson & Johnson Reports 2010 Fourth-Quarter and Full-Year Results
Date:1/25/2011

NEW BRUNSWICK, N.J., Jan. 25, 2011 /PRNewswire-FirstCall/ -- Johnson & Johnson (NYSE: JNJ) today announced sales of $15.6 billion for the fourth quarter of 2010, a decrease of 5.5% as compared to the fourth quarter of 2009. Operational sales declined 5.1% and the negative impact of currency was 0.4%. Domestic sales declined 8.1%, while international sales declined 3.1%, reflecting an operational decline of 2.3% and a negative currency impact of 0.8%. Worldwide sales for the full-year 2010 were $61.6 billion, a decrease of 0.5% versus 2009. Operational sales declined 1.3% and the positive impact of currency was 0.8%.  Domestic sales declined 4.7%, while international sales increased 3.6%, reflecting operational growth of 1.9% and a positive currency impact of 1.7%.

Net earnings and diluted earnings per share for the fourth quarter of 2010 were $1.9 billion and $0.70 respectively. Fourth-quarter 2010 net earnings included after-tax charges of $922 million representing the net impact of litigation settlements, product liability expense and costs associated with the DePuy ASR® Hip recall. Fourth-quarter 2009 net earnings included an after-tax restructuring charge of $852 million and an after-tax gain of $212 million representing the net impact of litigation settlements. Excluding these special items, net earnings for the current quarter were $2.9 billion and diluted earnings per share were $1.03, representing increases of 0.6% and 1.0%, respectively, as compared to the same period in 2009.*

Net earnings and diluted earnings per share for the full-year 2010 were $13.3 billion and $4.78, respectively. Full-year 2010 net earnings included an after-tax gain of $55 million representing the net impact of litigation settlements, product liability expense and costs associated with the DePuy ASR® Hip recall. Full-year 2009 net earnings included an after-tax restr
'/>"/>

SOURCE Johnson & Johnson
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related medicine technology :

1. Johnson & Johnson Provides Update on McNeil Consumer Healthcare Remediation; Announces Completion of Internal Assessment Phase of Comprehensive Action Plan
2. Reportlinker Adds Johnson & Johnson: PharmaVitae Profile
3. Boston Scientific Announces Election of Dr. Kristina M. Johnson to its Board of Directors
4. Johnson & Johnson Announces Executive Appointments: Alex Gorsky, Vice Chairman, Executive Committee Sheri McCoy, Vice Chairman, Executive Committee
5. Johnson & Johnson and Crucell Provide Progress Update on Preparations for Public Offer
6. Johnson & Johnson to Host Analyst Meeting to Discuss Third-Quarter Financial Results and Review Pharmaceutical Business
7. Two-Time Super Bowl Champion Coach & Sports Broadcaster Jimmy Johnson Laughs About His Notoriety in New ExtenZe Spots from Inter/Media Advertising
8. Surveyed European Oncologists Assign Greater Patient Share to Johnson & Johnsons Abiraterone Compared With Other Emerging Therapies in Asymptomatic or Minimally Symptomatic Metastatic Castrate-Resistant Prostate Cancer
9. Laureate Pharma Appoints Steven R. Johnson as Vice President, Business Development
10. Johnson & Johnson Completes Acquisition of Micrus Endovascular
11. SCOLR Pharma, Inc. Names Carl Johnson as Chairman; Former Chairman Michael Taglich Remains as Director
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... -- Omeros Corporation (NASDAQ: OMER ) today ... to evaluate OMS824 in Huntington,s disease has been ... (FDA). OMS824 selectively inhibits phosphodiesterase 10 (PDE10), an ... to a wide range of diseases that affect ... shown promising results in animal models directly relevant ...
(Date:5/23/2013)... , May 23, 2013  Inhibikase Therapeutics, Inc., ... today that it will present new results on ... industry conference sponsored by the PML Consortium (composed ... JC polyomavirus (JCV) is the causative agent of ... kinase inhibitor in an extended release formulation, can ...
(Date:5/23/2013)... -- InspireMD, Inc. ("InspireMD" or the ... protection stents, today announced new 6-month results from ... trial demonstrating that the MGuard Embolic Protection Stent ... in all-cause mortality in ST segment elevation myocardial ... presented at the InspireMD STEMI Symposium at EuroPCR, ...
Breaking Medicine Technology:Investigational New Drug Application Cleared by FDA for OMS824 in Huntington's Disease 2Investigational New Drug Application Cleared by FDA for OMS824 in Huntington's Disease 3Investigational New Drug Application Cleared by FDA for OMS824 in Huntington's Disease 4Inhibikase Therapeutics to present at Industry Conference on Drug-Induced Progressive Multifocal Leukoencephalopathy (PML) 2InspireMD's MGuard Embolic Protection Stent (EPS) Shows Lower Mortality Rate in STEMI Patients at Six Months Compared to Control Group 2InspireMD's MGuard Embolic Protection Stent (EPS) Shows Lower Mortality Rate in STEMI Patients at Six Months Compared to Control Group 3InspireMD's MGuard Embolic Protection Stent (EPS) Shows Lower Mortality Rate in STEMI Patients at Six Months Compared to Control Group 4InspireMD's MGuard Embolic Protection Stent (EPS) Shows Lower Mortality Rate in STEMI Patients at Six Months Compared to Control Group 5
... Bionovo, Inc. (Nasdaq: BNVI, BNVID), a drug discovery and development ... oncology, today announced that Dr. Isaac Cohen, O.M.D., Chairman and ... Healthcare Conference at 4:00 p.m. ET on Tuesday, September 28, ... Palace hotel in New York City. Interested parties ...
... Sept. 21 Anthera Pharmaceuticals, Inc. (Nasdaq: ... definitive agreements with certain accredited investors in connection with ... Section 4(2) of the Securities Act of 1933, as ... of the transaction, Anthera will receive gross proceeds of ...
Cached Medicine Technology:Bionovo to Present at the JMP Securities Healthcare Conference 2Anthera Pharmaceuticals Announces Pricing of $31.5 Million PIPE Financing 2Anthera Pharmaceuticals Announces Pricing of $31.5 Million PIPE Financing 3Anthera Pharmaceuticals Announces Pricing of $31.5 Million PIPE Financing 4
(Date:5/23/2013)... CT (PRWEB) May 23, 2013 Six ... a million dollars by Lyme Research Alliance, the nation's ... major academic institutions. The studies focus on the epidemiology of, ... diseases.  , “LRA is proud to support the ... and the brightest men and women in the field ...
(Date:5/23/2013)... (PRWEB) May 23, 2013 Elegance for a woman ... her flair, her taste, her intrigue can often be found in ... gateway to a woman's soul is through her eyes. It ... who she is! That is why the elegance of a woman ... . , Women today, more than any other time, utilize eyewear ...
(Date:5/23/2013)... Looking for tips on how to avoid ... of caring for your aging parent? Today the ... released the results of a survey of 335 geriatric care ... , Here are the top 5 tips identified by these ... survey respondents selecting each option): , 1.    Give each family member ...
(Date:5/23/2013)... Sika Sarnafil , the worldwide market leader ... Roof Systems of Iowa as the Recycling Project of ... during the re-roofing of the SuperTarget retail store in ... Elite contractor and one of Target’s Preferred Tier One ... sustainable building practices and they are a worthy recipient ...
(Date:5/23/2013)... According to a April 18, 2013 ... Found in Everyday Items Can Inhibit Fat Storage,” found ... as cosmetics and other products curb the storage of ... men and women who use such products experience accelerated ... wrinkles earlier than they otherwise would have (Go ...
Breaking Medicine News(10 mins):Health News:Six Investigators Awarded Lyme Research Alliance Grants 2Health News:Six Investigators Awarded Lyme Research Alliance Grants 3Health News:Six Investigators Awarded Lyme Research Alliance Grants 4Health News:Dolabany Eyewear Adds Feminine Flare to Women's Designer Eyewear with 2013 New Release of Adelina by Best Image Optical, Inc. 2Health News:New Survey of Aging Experts Gives Top 5 Tips for Avoiding Family Feud when Caring for Aging Parents 2Health News:Sika Sarnafil Announces Recycling Project of the Year Winner 2Health News:Aging and Wrinkles – Gold Found in Everyday Products Can Accelerate the Visual Signs of Aging 2
... a day after two minors died minutes after receiving ... district of Chhattisgarh. ,Two brothers, Umashanker, 6 years, ... they received injections for treatment of fever, cough and ... other members of the same family, who were also ...
... (also known as NRP104 or LDX) by Shire plc ... yielded a good response in children with Attention Deficit ... data was presented at a national meeting of child ... done on 269 children between 6 and 12 who ...
... from the University of California at Los Angeles (UCLA) ... resonance imaging (MRI) scan using the internet by an ... the remote scans were better in quality than the ... technology would benefit areas with inadequate staff members and ...
... farms with genetically modified papaya has led to suing ... called Greenpeace. ,Greenpeace is to take legal ... supply of genetically engineered papaya seeds to farmers throughout ... genetic engineering campaigner for Green Peace Southeast Asia, said, ...
... of harmful chemicals that may be present in some fish, ... ,Following the study of toxic substances in Puget Sound fish, ... Chinook salmon. ,Their study revealed that that Chinook ... mercury and PCBs, which is a banned industrial chemical. ...
... smoking cessation therapy used to help reduce adverse events ... of death for smokers admitted to// the intensive care ... 2006, the 72nd annual international scientific assembly of the ... smokers admitted to the ICU who received nicotine replacement ...
Cached Medicine News:Health News:Smoking Cessation Therapy May be Harmful for ICU Patients 2
To maintain the conjunctival cul-de-sacs after enucleation or evisceration without hindering lid closure....
To maintain the conjunctival cul-de-sacs after enucleation or evisceration without hindering lid closure....
... coated with a thin layer ... the surface slick as glass ... prevent debris from collecting on ... For partial stenosis. Silicone with ...
With side bite Instrument recommended to catch the polypropylene thread in the nose....
Medicine Products: